The odd thing about a blood test is how quickly it becomes history. A needle goes in. A report appears. The numbers are admired, feared or forwarded to a friend who owns a medical dictionary. Then everyone returns to lunch. Superpower, a preventive-health company founded in 2023, has built its business around the suspicion that the lonely report is the wrong unit of medicine. A test should be the beginning of a conversation - and, eventually, another test.
- Superpower's current US membership costs $349 a year and advertises two annual blood draws covering 150-plus biomarkers.
- Members receive a dashboard, a personalized protocol, AI-assisted answers and access to a human care team.
- Its closest alternative is Function Health; concierge clinics offer more attention at a much higher price, while ordinary primary care remains less standardized and usually less broad.
- The useful idea to copy is the loop: measure, choose a small intervention, set a date, measure again.
A report card for the body
Superpower begins with a broad panel. The company groups markers across cardiovascular, metabolic, thyroid, hormone, liver, kidney, nutrient, immune and other systems. Past Quest or Labcorp results can be uploaded; wearables including Oura, Whoop and Apple Health can be connected. The software turns the mixture into trends, system-level grades, a biological-age estimate and a plan.
This is the first important translation. A conventional lab portal is organized for record keeping. Superpower is organized for deciding. Its protocol may include diet, exercise, supplements and retesting timelines. The AI layer can explain a result in the context of the member's own data; the care team steps in when a question requires deeper review. Optional gut, toxin and cancer screens sit nearby, as do supplements and clinician-evaluated prescriptions.
Five businesses are tucked into this arrangement: laboratory logistics, medical interpretation, health-record storage, conversational software and a marketplace. The annual fee hides the joins. A member books at one of more than 2,000 partner laboratory locations, or requests an at-home draw where available, and receives results in the app. The elegant part is not that any one piece is new. It is that the pieces remember one another.
The return trip changes the meaning
The current membership includes a baseline draw and a retest. That modest second appointment changes the psychology of the first. Without it, a recommendation can remain a tasteful aspiration: eat differently, sleep longer, take the supplement, call your doctor. With it, the advice acquires a deadline and a question. Did the number move?
This is what another company can copy without collecting a drop of blood. Do not sell a dashboard; design a return journey. Give a customer a baseline, prescribe one legible action, declare when the result will be checked, then make the comparison unavoidable. Fitness apps do this with streaks. Financial tools do it with monthly close. Superpower applies the same grammar to biomarkers.
“The interesting product is not more information. It is a reason to come back and discover whether the information was useful.”
Two founders, two failures of timing
The company's origin story is unusually symmetrical. Jacob Peters has said a severe health crisis put him in intensive care for more than three months and produced a multimillion-dollar bill. What changed his view was the contrast between the reactive, uniform care he had received and the proactive, integrative care available privately to people with money and access.
Max Marchione describes a different failure. He says he spent a decade being misdiagnosed, saw roughly 20 doctors, underwent surgery and was told he would need medication for life. The first thing that failed, in both stories, was timing: useful attention arrived after the situation had become expensive, chronic or both. Peters, Marchione and technical co-founder Kevin Unkrich started Superpower in 2023 to pull that attention forward.
Their first public financing was a $4 million pre-seed led by Susa Ventures in 2024. The following April, after building a reported 150,000-person waitlist, Superpower launched publicly and announced a $30 million Series A led by Forerunner Ventures. The investor list mixed venture firms with entertainers, athletes and founders. It fit the company: part clinic, part consumer brand.
The price is also a product decision
Superpower's offer has not stood still. The public product launched with a $499 price, moved to a $199 membership in August 2025, and now advertises $349 with a second annual draw and more than 150 biomarkers. Those are not interchangeable deals. Any comparison that freezes one price and another year's feature list produces a tidy fiction.
At the current price, the closest comparison is Function Health, another broad biomarker membership. InsideTracker offers a narrower core panel with a longer history in recommendations and DNA-linked products. Mito Health and Hundred Health occupy adjacent territory. An ordinary doctor may order only the tests indicated by age, symptoms and guidelines; a concierge longevity clinic can provide much more conversation, but often at many times the cost.
Superpower's difference is its bundle: national lab access, a consumer-grade interface, personalized protocols, AI explanations, human support and a store of additional services. The customer is not necessarily ill. It is the person who suspects that “fine” is a poor organizing principle for the next 20 years.
Superpower says 60% of surveyed members found something a doctor had missed, 77% learned something new and 93% rated the service more useful than a checkup. The sample was 143 members surveyed 90 days after receiving an action plan. Those are interesting customer reports, not evidence that broad screening improves long-term clinical outcomes.
The dashboard is not the doctor
Broad testing has a predictable weakness: every extra marker is another opportunity to discover a harmless abnormality. Reference ranges are not diagnoses. Biological-age scores can differ across platforms because the formulas differ. An anxious customer may experience 150 measurements as 150 small emergencies. The model works best for someone willing to discuss consequential findings with a clinician, change a few behaviors and return for comparable testing under similar conditions.
It works less well when more data becomes reassurance-seeking, when the result demands specialist care the platform cannot provide, or when a person expects prevention to substitute for treatment. It also asks the customer to trust a company with an unusually intimate archive: labs, records, goals, wearable signals and conversation history. The convenience and the privacy exposure come from the same integration.
There is a commercial tension, too. Superpower can interpret a result and then offer the supplement, specialty test or therapy that follows. That may reduce friction; it can also create incentives to keep the next step inside the marketplace. Good product design cannot abolish that conflict. Clear clinical boundaries, transparent pricing and the freedom to take results to an outside physician matter.
What the second vial buys
Superpower is often described by its largest number: 150-plus biomarkers. The more revealing number is two. The first draw creates a map. The second creates accountability. Between them sits the company's real work - deciding which signals deserve attention, converting them into actions a person will actually take, and admitting when software should yield to a clinician.
A better annual physical is an attractive promise. A repeatable method for learning what changed is a more disciplined one. Superpower has not solved the old problem that health is noisy, behavior is difficult and more measurement can produce more confusion. It has, however, designed a product around the moment most lab reports ignore: lunch is over, three months have passed, and now we find out whether any of it worked.